Vaishali Pharma Ltd.

As of March 31, 2025, Vaishali Pharma Ltd. carries a market capitalization of 1.64B, placing it among publicly traded companies globally. Its enterprise value stands at 1.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Vaishali Pharma Ltd. has 130.46M shares outstanding.

As of March 31, 2025, Vaishali Pharma Ltd. trades at a trailing price-to-earnings ratio of 194.71. The price-to-sales ratio is 1.63, and the price-to-book ratio stands at 2.53.

As of March 31, 2025, Vaishali Pharma Ltd. trades at an EV/EBITDA multiple of 207.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 488.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.75B versus a market cap of 1.64B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2025, Vaishali Pharma Ltd. maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.98, indicating elevated leverage, while an interest coverage ratio of 0.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Vaishali Pharma Ltd. posted a return on equity (ROE) of 1.52, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.36 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.29, useful for judging operating efficiency across full business cycles. The company generates approximately 36.25M in revenue per employee across its workforce of 27.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 33.02 indicates how many times Vaishali Pharma Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2025, Vaishali Pharma Ltd. recorded 4.08M in income tax expense. That works out to an effective tax rate of 33.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.26M, leaving 8.17M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Vaishali Pharma Ltd.'s stock has declined approximately 29.87% over the past 52 weeks. The 50-day moving average sits at 8.24, while the 200-day moving average is 7.63.

Over the twelve months ended March 31, 2025, Vaishali Pharma Ltd. generated 978.82M in revenue and converted that into 8.17M in net income, yielding earnings per share of 0.06. EBITDA reached 8.44M, while operating income came in at 59.00M.

As of March 31, 2025, Vaishali Pharma Ltd. holds 17.11M in cash and equivalents against 123.18M in total debt, resulting in a net debt position of 99.49M. Total book value stands at 649.16M, with working capital of 644.31M providing operational flexibility.

Over the twelve months ended March 31, 2025, Vaishali Pharma Ltd. posted a gross margin of 12.47, reflecting its pricing power and cost economics. The operating margin of 6.03 and net profit margin of 0.84 provide insight into operational efficiency.

Vaishali Pharma Ltd.'s most recent stock split took place on October 15, 2024 with a 1:10 split ratio.

As of March 31, 2025, Vaishali Pharma Ltd. has an Altman Z-Score of 4.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.